CVS Stock Down on Early Warnings About 2027

Dow Jones08-05 21:54

CVS Health saw its shares dip about 6% even though it handily beat Wall Street's expectations for the most recent quarter and raised its guidance for 2026 earnings. The issue was the company's unusually early commentary about 2027.

The healthcare giant warned that membership in its Caremark pharmacy-benefits manager will decline next year, as it rewrites contracts to reflect a new pricing model and as some of its insurer clients pull back from certain markets. The warning comes amid broader investor concern about the evolving financial model of PBMs.

The company also flagged pressures related to the 340B drug-discount program. CVS offered a more upbeat view of continued improvements at Aetna, its insurance arm.

CVS said the current consensus adjusted earnings estimate for 2027 is a reasonable floor. The company remains confident in its forecast of mid-teens earnings growth through 2028. "We have some pressure in our PBM at the moment, more than offset by the strength we have across the enterprise," said CEO David Joyner.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2657540015?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-05 21:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2657540015","market":"sg","top_or_hot":-1,"title":"CVS Stock Down on Early Warnings About 2027","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     CVS Health saw its shares dip about 6% even though it handily beat Wall Street's expectations for the most recent quarter and raised its guidance for 2026 earnings. The issue was the company's unusually early commentary about 2027. \n</p>\n<p>\n     The healthcare giant warned that membership in its Caremark pharmacy-benefits manager will decline next year, as it rewrites contracts to reflect a new pricing model and as some of its insurer clients pull back from certain markets. The warning comes amid broader investor concern about the evolving financial model of PBMs. \n</p>\n<p>\n     The company also flagged pressures related to the 340B drug-discount program. CVS offered a more upbeat view of continued improvements at Aetna, its insurance arm. \n</p>\n<p>\n     CVS said the current consensus adjusted earnings estimate for 2027 is a reasonable floor. The company remains confident in its forecast of mid-teens earnings growth through 2028. \"We have some pressure in our PBM at the moment, more than offset by the strength we have across the enterprise,\" said CEO David Joyner. \n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CVS Stock Down on Early Warnings About 2027</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCVS Stock Down on Early Warnings About 2027\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-08-05 21:54</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     CVS Health saw its shares dip about 6% even though it handily beat Wall Street's expectations for the most recent quarter and raised its guidance for 2026 earnings. The issue was the company's unusually early commentary about 2027. \n</p>\n<p>\n     The healthcare giant warned that membership in its Caremark pharmacy-benefits manager will decline next year, as it rewrites contracts to reflect a new pricing model and as some of its insurer clients pull back from certain markets. The warning comes amid broader investor concern about the evolving financial model of PBMs. \n</p>\n<p>\n     The company also flagged pressures related to the 340B drug-discount program. CVS offered a more upbeat view of continued improvements at Aetna, its insurance arm. \n</p>\n<p>\n     CVS said the current consensus adjusted earnings estimate for 2027 is a reasonable floor. The company remains confident in its forecast of mid-teens earnings growth through 2028. \"We have some pressure in our PBM at the moment, more than offset by the strength we have across the enterprise,\" said CEO David Joyner. \n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2657540015","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2657540015","pubTimestamp":1785938040,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"CVS Health saw its shares dip about 6% even though it handily beat Wall Street's expectations for the most recent quarter and raised its guidance for 2026 earnings. The issue was the company's unusually early commentary about 2027.The healthcare giant warned that membership in its Caremark pharmacy-benefits manager will decline next year, as it rewrites contracts to reflect a new pricing model and as some of its insurer clients pull back from certain markets. The warning comes amid broader investor concern about the evolving financial model of PBMs.The company also flagged pressures related to the 340B drug-discount program. CVS offered a more upbeat view of continued improvements at Aetna, its insurance arm.CVS said the current consensus adjusted earnings estimate for 2027 is a reasonable floor. The company remains confident in its forecast of mid-teens earnings growth through 2028. \"We have some pressure in our PBM at the moment, more than offset by the strength we have across the en","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","BK4550":"红杉资本持仓","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC","LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC","BK4196":"保健护理服务","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","CVS":"西维斯健康","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","BK4581":"高盛持仓","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","BK4585":"ETF&股票定投概念","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1923622614.USD":"Natixis Thematics Meta R/A USD","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","RTH":"零售指数ETF-HOLDRs","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","LU0859254822.USD":"T ROWE PRICE GLOBAL VALUE EQUITY \"A\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","LU2357627491.SGD":"TRP GLOBAL VALUE EQUITY \"AH\" (SGDHDG) ACC","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","IHF":"iShares Dow Jones U.S. Health Ca","BK4504":"桥水持仓","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD"},"translate_title":"CVS 库存因 2027 年左右的预警而下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RTH":0.6,"CVS":1.5,"IHF":0.6},"content_text":"CVS Health saw its shares dip about 6% even though it handily beat Wall Street's expectations for the most recent quarter and raised its guidance for 2026 earnings. The issue was the company's unusually early commentary about 2027. \n\n\n     The healthcare giant warned that membership in its Caremark pharmacy-benefits manager will decline next year, as it rewrites contracts to reflect a new pricing model and as some of its insurer clients pull back from certain markets. The warning comes amid broader investor concern about the evolving financial model of PBMs. \n\n\n     The company also flagged pressures related to the 340B drug-discount program. CVS offered a more upbeat view of continued improvements at Aetna, its insurance arm. \n\n\n     CVS said the current consensus adjusted earnings estimate for 2027 is a reasonable floor. The company remains confident in its forecast of mid-teens earnings growth through 2028. \"We have some pressure in our PBM at the moment, more than offset by the strength we have across the enterprise,\" said CEO David Joyner.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2657540015","isCrawlerRequest":true}